1. Home
  2. OPAD vs IMUX Comparison

OPAD vs IMUX Comparison

Compare OPAD & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OPAD

Offerpad Solutions Inc.

HOLD

Current Price

$1.58

Market Cap

89.3M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.62

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPAD
IMUX
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.3M
85.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OPAD
IMUX
Price
$1.58
$0.62
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$2.54
$6.00
AVG Volume (30 Days)
776.5K
1.2M
Earning Date
11-03-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$627,966,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.56
52 Week High
$6.35
$1.39

Technical Indicators

Market Signals
Indicator
OPAD
IMUX
Relative Strength Index (RSI) 36.38 36.87
Support Level $1.81 $0.66
Resistance Level $2.03 $0.70
Average True Range (ATR) 0.15 0.04
MACD 0.02 -0.00
Stochastic Oscillator 2.04 25.81

Price Performance

Historical Comparison
OPAD
IMUX

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: